Inflammation modulates anxiety in an animal model of multiple sclerosis
ABSTRACT Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) characterized by inflammation, but also degenerative changes. Besides neurological deficits, the rate of affective disorders such as depression and anxiety is at least six fold increased. Many aspects of MS can be mimicked in the animal model of myelin oligodendrocyte glycoprotein experimental autoimmune encephalomyelitis (MOG-EAE). Here we investigate behavioral changes in C57BL/6 mice suffering from mild MOG-EAE. In the later phase of the disease, mice were subjected to behavioral tests including the light-dark-box (LD Box), the acoustic startle response (SR) with a pre-pulse inhibition protocol as well as the learned helplessness (LH) paradigm. Behavioral data were correlated with the motor performance in an open field and rotarod test (RR). In the RR and open field, there was no significant difference in the motor performance between controls and mice suffering from mild MOG-EAE. Yet EAE mice displayed an increased anxiety-like behavior with a 23% reduction of the time spent in the bright compartment of the LD Box as well as an increased SR. In the LH paradigm, mice suffering from MOG-EAE were twice as much prone to depressive-like behavior. These changes correlate with an increase of hippocampal tissue tumor necrosis factor alpha levels and neuronal loss in the hippocampus. Modulation of monoaminergic transmission by chronic application of the antidepressant amitriptyline resulted in a decreased startle reaction and increased hippocampal norepinephrine levels. These data imply that chronic inflammation in the CNS may impact on emotional responses in rodent models of anxiety.
- SourceAvailable from: Heba Mohamed Fahmy
[Show abstract] [Hide abstract]
- "In the present work, rats of the ''EAE'' group spent significantly more time in the center compared to the other tested groups. It may be suggested that the rats of the ''EAE'' group showed higher exploratory and lower anxiety behavior levels besides less emotion with respect to other groups, which is inconsistent with the findings of the previous studies (Peruga et al., 2011; Rodrigues et al., 2011). "
ABSTRACT: Experimental autoimmune encephalomyelitis (EAE) is a well-established animal model of multiple sclerosis. This study aimed to investigate the protective and therapeutic effects of Nigella sativa (N. sativa) seeds (2.8 g/kg body weight) in EAE-induced rats. EAE-induced animals were divided into: (1) EAE-induced animals (“EAE” group). (2) “N. sativa + EAE” group received a daily oral administration of N. sativa 2 weeks prior to EAE induction until the end of the experiment. (3) “EAE + N. sativa” group received a daily oral administration of N. sativa after the appearance of the first clinical signs until the end of the experiment. All animals were sacrificed at the 28th day post EAE-induction. Disease pathogenesis was monitored using a daily clinical scoring, body weight, open field test, histopathological and ultrastructural examination and determination of some oxidative stress parameters in the cortex and hippocampus. N. sativa ameliorated the clinical signs and suppressed inflammation observed in EAE-induced rats. In addition, N. sativa enhanced remyelination in the hippocampus. However, protection of rats with N. sativa administered 2 weeks prior to EAE induction and its continuation until the end of the experiment resulted in a significant increase in the cortical lipid peroxide level with reference to control and “EAE” rats. In conclusion, N. sativa seeds could be used as a protective agent or an adjunct treatment for EAE even when the treatment started after the appearance of the first clinical signs. However, the dose and duration of N. sativa must be taken into consideration to avoid its probable pro-oxidant effect.09/2014; 67(5). DOI:10.1016/j.jobaz.2014.08.005
[Show abstract] [Hide abstract]
- "Genetic risk factors have only been partially identified, implying HLA- DR alleles to be associated with increased risk of depression in MS (Schiffer et al. 1988) and ApoE ε2 alleles as having a protective effect (Julian et al. 2009). In a rodent model of MS, higher hippocampal TNF-α levels positively correlated with depressive symptoms (Peruga et al. 2011), while in another study peripheral TNF-α and interferon-γ (IFN-γ) mRNA correlated with the severity of depressive symptoms during an acute exacerbation in MS patients (Kahl et al. 2002). Structural neuroimaging techniques provide further evidence regarding the pathophysiology of depression and anxiety in MS, demonstrating the risk of depression to be associated with a higher lesion load in the medial inferior prefrontal cortex and the anterior temporal lobe of the dominant hemisphere, as well as with atrophy of the dominant anterior temporal lobe (Pujol et al. 1997; Bakshi et al. 2000; Feinstein et al. 2004). "
ABSTRACT: Laquinimod is a novel oral immunomodulatory drug for the treatment of multiple sclerosis (MS). Considering the frequent co-morbidity of MS with anxiety and depression, we sought to assess the antidepressant and anxiolytic effects of laquinimod in mouse models. Laquinimod (0.5-25 mg/kg), fluoxetine (10 mg/kg) or vehicle were administered for 4-14 days to adult Balb/c mice, followed by behavioral tests and brain BDNF analysis. Following a 4-day administration of laquinimod (5 and 25 mg/kg), an increase in motivated behavior was observed in the forced swim test (p < 0.01 vs. controls). In the open field test, laquinimod (0.5-5 mg/kg), but not fluoxetine, significantly increased motility (p < 0.05), whereas both decreased anxiety behavior (p < 0.01), evident only for laquinimod (5 mg/kg) in the elevated plus maze (p < 0.05). Following 7 days of administration, both drugs decreased anxiety behavior in the elevated plus maze and marble burying tests (p < 0.001 and p < 0.02, respectively). After 14 days, only laquinimod (5 mg/kg) demonstrated anxiolytic efficacy in the open field test (p < 0.05), with evidence of increased BDNF in response to 5-25 mg/kg in the hippocampus, but not frontal cortex (p < 0.05). In conclusion, laquinimod may possess anxiolytic and antidepressant effects, possibly associated with hippocampal BDNF increase, offering promise for MS patients suffering from psychiatric co-morbidity.Journal of Molecular Neuroscience 07/2014; 55(2). DOI:10.1007/s12031-014-0387-3 · 2.76 Impact Factor
[Show abstract] [Hide abstract]
- "These studies reported either no changes (24) or an inverse correlation between social exploration and the rise of inflammatory mediators including IL-1, TNF-α, and PGE2 (25). Conversely, Peruga et al. demonstrated that mice immunized with a suboptimal dose of MOG35–55 (50 μg) showed the manifestation of motor impairment at day 60 after immunization and had an increase anxiety-like behavior that correlated with an increase in the level of TNF-α and with neuronal loss in the hippocampus (26). This was also associated with a doubled depressive-like behavior in the learned helplessness paradigm. "
ABSTRACT: Autoimmune diseases like multiple sclerosis (MS) are known to be associated with debilitating emotional disorders that manifest long before the flaring of motor dysfunctions. Given the emerging role of T cells in controlling both emotions and autoimmunity, in this study we explored possible correlation between T cell activation and changes in emotional behavior in a mouse model of MS. Our results showed a significant increase in blood circulating T cells as soon as at day 4 post immunization. This lymphocytosis remained stable with time and preceded the infiltration of T cell in the CNS. The kinetic of T cell entry in the blood matched the kinetic of changes in behavior measured using the open field test. Treatment with glatiramer acetate, a well-known immunomodulatory drug for MS, suppressed behavioral changes while retaining the T cells in the draining lymph nodes. Together these results provide evidence of a positive correlation between the emigration of T cells in circulation and changes in emotions during chronic inflammatory diseases. The validation of these findings in the clinic might help to better understand the cause of the emotional and psychological burden of patients suffering MS or other autoimmune diseases. Most importantly our study suggests novel therapeutic venues for the treatment of the emotional changes associated with autoimmunity.Frontiers in Immunology 11/2013; 4:400. DOI:10.3389/fimmu.2013.00400